Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
about
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesCervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural EthiopiaPre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsThe DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.Identification of the skin virome in a boy with widespread human papillomavirus-2-positive warts that completely regressed after administration of tetravalent human papillomavirus vaccine.
P2860
Q28085724-2D594456-ABF6-4F39-8AE5-F9593D79EB06Q34340212-0ED63B54-5C2E-42F1-B358-0FF4C28B4EF9Q34492140-4628DC62-BBE0-4023-AEDD-8D760F8ECE5AQ37526148-A384DF67-2B2F-4ADA-BF4B-38A28C057933Q38229304-9CA53685-811C-4DFB-B77C-A60587AF3C79Q38370782-7D67DCAB-C187-410C-B677-56B8487D4A56Q38869506-FA031956-EB6A-472E-9C36-3CD74B0D7EF8Q40129472-ADE404E3-7F85-46A0-9C2F-6C21AC93B099Q40721764-F843841C-E8AE-4CEC-8782-C3A025A724BBQ48230417-69B6EFEA-AF7E-4772-AE01-BD52A9FE63DB
P2860
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@en
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@nl
type
label
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@en
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@nl
prefLabel
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@en
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@nl
P2093
P2860
P1433
P1476
Cross-neutralizing antibodies ...... ha-9 inter-type specificities.
@en
P2093
Eve Draper
Richard E Myers
Sara L Bissett
P2860
P304
P356
10.1016/J.VACCINE.2014.01.008
P407
P50
P577
2014-01-15T00:00:00Z